Do analysts prefer ARIX or 4BB?

4basebio has a consensus target price of GBX 1,400, indicating a potential upside of 181.80%. Given 4basebio's stronger consensus rating and higher probable upside, analysts clearly believe 4basebio is more favorable than Arix Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arix Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 4basebio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts rate 4BB or CIR?

4basebio presently has a consensus target price of GBX 1,400, suggesting a potential upside of 181.80%. Given 4basebio's stronger consensus rating and higher probable upside, research analysts plainly believe 4basebio is more favorable than Circassia Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 4basebio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Circassia Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is 4BB or CIR more profitable?

Circassia Group's return on equity of 0.00% beat 4basebio's return on equity. Company Net Margins Return on Equity Return on Assets 4basebio N/A -231.29% -54.30% Circassia Group N/A N/A N/A

Do analysts recommend TILS or 4BB?

4basebio has a consensus target price of GBX 1,400, indicating a potential upside of 181.80%. Given 4basebio's stronger consensus rating and higher probable upside, analysts clearly believe 4basebio is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 4basebio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is TILS or 4BB more profitable?

Tiziana Life Sciences' return on equity of 0.00% beat 4basebio's return on equity. Company Net Margins Return on Equity Return on Assets Tiziana Life Sciences N/A N/A N/A 4basebio N/A -231.29% -54.30%

Do analysts rate 4BB or VSN?

4basebio currently has a consensus target price of GBX 1,400, suggesting a potential upside of 181.80%. Given 4basebio's stronger consensus rating and higher probable upside, research analysts plainly believe 4basebio is more favorable than Verseon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 4basebio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Verseon 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is 4BB or VSN more profitable?

Verseon's return on equity of 0.00% beat 4basebio's return on equity. Company Net Margins Return on Equity Return on Assets 4basebio N/A -231.29% -54.30% Verseon N/A N/A N/A

Do analysts prefer 4BB or SCLP?

4basebio presently has a consensus target price of GBX 1,400, suggesting a potential upside of 181.80%. Given 4basebio's stronger consensus rating and higher possible upside, research analysts plainly believe 4basebio is more favorable than Scancell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 4basebio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Scancell 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation & earnings, 4BB or SCLP?

Scancell has higher revenue and earnings than 4basebio. Scancell is trading at a lower price-to-earnings ratio than 4basebio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 4basebio £1.69M 45.44 -£9.84M -£109.00 N/A Scancell £4.71M 23.04 -£6.75M -£0.55 N/A

Is 4BB or SCLP more profitable?

4basebio has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat 4basebio's return on equity. Company Net Margins Return on Equity Return on Assets 4basebio N/A -231.29% -54.30% Scancell -116.98% 90.29% -45.28%

Does the media prefer 4BB or SCLP?

In the previous week, 4basebio and 4basebio both had 1 articles in the media. 4basebio's average media sentiment score of 0.71 beat Scancell's score of 0.67 indicating that 4basebio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4basebio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scancell 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

4basebio (4BB) Competitors

GBX 496.80 +16.80 (+3.50%)

As of 09/11/2026 11:15 AM Eastern

Compare

4BB vs. ARIX, CIR, TILS, VSN, and SCLP

Should you buy 4basebio stock or one of its competitors? 4basebio's main competitors and comparable companies include Arix Bioscience (ARIX), Circassia Group (CIR), Tiziana Life Sciences (TILS), Verseon (VSN), and Scancell (SCLP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does 4basebio compare to Arix Bioscience?

Arix Bioscience (LON:ARIX) and 4basebio (LON:4BB) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

Arix Bioscience has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, 4basebio has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

4basebio has a consensus target price of GBX 1,400, indicating a potential upside of 181.80%. Given 4basebio's stronger consensus rating and higher probable upside, analysts clearly believe 4basebio is more favorable than Arix Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arix Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, 4basebio had 1 more articles in the media than Arix Bioscience. MarketBeat recorded 1 mentions for 4basebio and 0 mentions for Arix Bioscience. 4basebio's average media sentiment score of 0.71 beat Arix Bioscience's score of 0.00 indicating that 4basebio is being referred to more favorably in the news media.

Company	Overall Sentiment
Arix Bioscience	Neutral
4basebio	Positive

Arix Bioscience has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A
4basebio	£1.69M	45.44	-£9.84M	-£109.00	N/A

41.3% of Arix Bioscience shares are held by institutional investors. Comparatively, 0.9% of 4basebio shares are held by institutional investors. 20.7% of Arix Bioscience shares are held by insiders. Comparatively, 12.1% of 4basebio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Arix Bioscience has a net margin of 105.64% compared to 4basebio's net margin of 0.00%. Arix Bioscience's return on equity of 6.41% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arix Bioscience	105.64%	6.41%	2.18%
4basebio	N/A	-231.29%	-54.30%

Summary

Arix Bioscience beats 4basebio on 9 of the 15 factors compared between the two stocks.

How does 4basebio compare to Circassia Group?

4basebio (LON:4BB) and Circassia Group (LON:CIR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

In the previous week, 4basebio had 1 more articles in the media than Circassia Group. MarketBeat recorded 1 mentions for 4basebio and 0 mentions for Circassia Group. 4basebio's average media sentiment score of 0.71 beat Circassia Group's score of 0.00 indicating that 4basebio is being referred to more favorably in the media.

Company	Overall Sentiment
4basebio	Positive
Circassia Group	Neutral

Circassia Group has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4basebio	£1.69M	45.44	-£9.84M	-£109.00	N/A
Circassia Group	£27.90M	0.00	N/A	£0.01	N/A

Circassia Group's return on equity of 0.00% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4basebio	N/A	-231.29%	-54.30%
Circassia Group	N/A	N/A	N/A

4basebio presently has a consensus target price of GBX 1,400, suggesting a potential upside of 181.80%. Given 4basebio's stronger consensus rating and higher probable upside, research analysts plainly believe 4basebio is more favorable than Circassia Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Circassia Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

0.9% of 4basebio shares are held by institutional investors. 12.1% of 4basebio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

4basebio beats Circassia Group on 7 of the 12 factors compared between the two stocks.

How does 4basebio compare to Tiziana Life Sciences?

Tiziana Life Sciences (LON:TILS) and 4basebio (LON:4BB) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

Tiziana Life Sciences has higher earnings, but lower revenue than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	-£3.60M	0.00	N/A	-£16.30	N/A
4basebio	£1.69M	45.44	-£9.84M	-£109.00	N/A

In the previous week, 4basebio had 1 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 1 mentions for 4basebio and 0 mentions for Tiziana Life Sciences. 4basebio's average media sentiment score of 0.71 beat Tiziana Life Sciences' score of 0.00 indicating that 4basebio is being referred to more favorably in the news media.

Company	Overall Sentiment
Tiziana Life Sciences	Neutral
4basebio	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

0.9% of 4basebio shares are held by institutional investors. 12.1% of 4basebio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Tiziana Life Sciences' return on equity of 0.00% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
4basebio	N/A	-231.29%	-54.30%

Summary

4basebio beats Tiziana Life Sciences on 8 of the 12 factors compared between the two stocks.

How does 4basebio compare to Verseon?

4basebio (LON:4BB) and Verseon (LON:VSN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

4basebio currently has a consensus target price of GBX 1,400, suggesting a potential upside of 181.80%. Given 4basebio's stronger consensus rating and higher probable upside, research analysts plainly believe 4basebio is more favorable than Verseon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Verseon	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, 4basebio had 1 more articles in the media than Verseon. MarketBeat recorded 1 mentions for 4basebio and 0 mentions for Verseon. 4basebio's average media sentiment score of 0.71 beat Verseon's score of 0.00 indicating that 4basebio is being referred to more favorably in the media.

Company	Overall Sentiment
4basebio	Positive
Verseon	Neutral

Verseon's return on equity of 0.00% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4basebio	N/A	-231.29%	-54.30%
Verseon	N/A	N/A	N/A

Verseon has lower revenue, but higher earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4basebio	£1.69M	45.44	-£9.84M	-£109.00	N/A
Verseon	N/A	N/A	N/A	-£14.30	N/A

Summary

4basebio beats Verseon on 9 of the 12 factors compared between the two stocks.

How does 4basebio compare to Scancell?

4basebio (LON:4BB) and Scancell (LON:SCLP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

4basebio has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Scancell has a beta of 0.687, indicating that its stock price is 31% less volatile than the broader market.

Scancell has higher revenue and earnings than 4basebio. Scancell is trading at a lower price-to-earnings ratio than 4basebio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4basebio	£1.69M	45.44	-£9.84M	-£109.00	N/A
Scancell	£4.71M	23.04	-£6.75M	-£0.55	N/A

0.9% of 4basebio shares are owned by institutional investors. Comparatively, 1.5% of Scancell shares are owned by institutional investors. 12.1% of 4basebio shares are owned by insiders. Comparatively, 13.2% of Scancell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

4basebio has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4basebio	N/A	-231.29%	-54.30%
Scancell	-116.98%	90.29%	-45.28%

4basebio presently has a consensus target price of GBX 1,400, suggesting a potential upside of 181.80%. Given 4basebio's stronger consensus rating and higher possible upside, research analysts plainly believe 4basebio is more favorable than Scancell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Scancell	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, 4basebio and 4basebio both had 1 articles in the media. 4basebio's average media sentiment score of 0.71 beat Scancell's score of 0.67 indicating that 4basebio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4basebio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scancell	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

4basebio beats Scancell on 8 of the 15 factors compared between the two stocks.

Get 4basebio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

4BB vs. The Competition

Export

Metric	4basebio	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£76.93M	£3.86B	£7.15B	£2.87B
Dividend Yield	N/A	3.63%	2.56%	6.22%
P/E Ratio	-4.56	14.11	272.98	366.83
Price / Sales	45.44	1,415.79	642.14	83,599.70
Price / Cash	16.08	106.68	77.04	27.89
Price / Book	-12.12	15.13	10.33	6.33
Net Income	-£9.84M	-£22.82M	£3.49B	£5.89B
7 Day Performance	-0.64%	-4.31%	-3.33%	-0.69%
1 Month Performance	-9.67%	0.00%	-0.40%	0.18%
1 Year Performance	-41.55%	40.67%	19.15%	20.03%

4basebio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
4BB 4basebio	1.809 of 5 stars	GBX 496.80 +3.5%	GBX 1,400 +181.8%	-41.6%	£76.93M	£1.69M	N/A	101	Gap Up
ARIX Arix Bioscience	N/A	N/A	N/A	N/A	£183.73M	£14.16M	1,290.91	9
CIR Circassia Group	N/A	N/A	N/A	N/A	£142.66M	£27.90M	3,400.00	111	Gap Down
TILS Tiziana Life Sciences	N/A	N/A	N/A	N/A	£113.85M	-£3.60M	N/A	11
VSN Verseon	N/A	N/A	N/A	N/A	£112.24M	N/A	N/A	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:4BB) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

4basebio (4BB) Competitors

4BB vs. ARIX, CIR, TILS, VSN, and SCLP

How does 4basebio compare to Arix Bioscience?

Summary

How does 4basebio compare to Circassia Group?

Summary

How does 4basebio compare to Tiziana Life Sciences?

Summary

How does 4basebio compare to Verseon?

Summary

How does 4basebio compare to Scancell?

Summary

Media Sentiment Over Time

4BB vs. The Competition

4basebio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

4basebio (4BB) Competitors

4BB vs. ARIX, CIR, TILS, VSN, and SCLP

How does 4basebio compare to Arix Bioscience?

Which has more risk & volatility, ARIX or 4BB?

Do analysts prefer ARIX or 4BB?

Does the media refer more to ARIX or 4BB?

Which has stronger earnings & valuation, ARIX or 4BB?

Do insiders and institutionals believe in ARIX or 4BB?

Is ARIX or 4BB more profitable?

Summary

How does 4basebio compare to Circassia Group?

Does the media prefer 4BB or CIR?

Which has higher earnings and valuation, 4BB or CIR?

Is 4BB or CIR more profitable?

Do analysts rate 4BB or CIR?

Do insiders & institutionals hold more shares of 4BB or CIR?

Summary

How does 4basebio compare to Tiziana Life Sciences?

Which has higher valuation & earnings, TILS or 4BB?

Does the media refer more to TILS or 4BB?

Do analysts recommend TILS or 4BB?

Do institutionals & insiders believe in TILS or 4BB?

Is TILS or 4BB more profitable?

Summary

How does 4basebio compare to Verseon?

Do analysts rate 4BB or VSN?

Does the media refer more to 4BB or VSN?

Do insiders and institutionals hold more shares of 4BB or VSN?

Is 4BB or VSN more profitable?

Which has stronger earnings and valuation, 4BB or VSN?

Summary

How does 4basebio compare to Scancell?

Which has more risk and volatility, 4BB or SCLP?

Which has stronger valuation & earnings, 4BB or SCLP?

Do insiders & institutionals hold more shares of 4BB or SCLP?

Is 4BB or SCLP more profitable?

Do analysts prefer 4BB or SCLP?

Does the media prefer 4BB or SCLP?

Summary

Media Sentiment Over Time

4BB vs. The Competition

4basebio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools